Under $1 again, Titan Pharmaceuticals, Inc. (OTCBB:TTNP) Keeps Silence, Awaits November Verdicts
Titan Pharmaceuticals, Inc. (OTCBB:TTNP) is flirting again with the $1 levels, standing at 92 cents after adding more than 9% on dollar volumes above 400K. While TTNP remains relatively active, we are not seeing the rally and recovery that was expected sooner rather than later. 
Investors’ forums are still full of optimism, stating that TTNP is still a steal at those prices. And the time between now and the FDA review meeting on November 19th is getting narrower, which may add upward pressure to the price.
The company has been silent with press releases for nearly a month, gathering up presentation data and mostly betting on a positive verdict. Some negative news have slipped through the silence- that TTNP has not made new trials or improvements since the voting this spring. Also, the company was hoping for a B-meeting, and now will receive the lower attention of a C-type meeting.
TTNP now faces the end-of-the week drama, where selling may begin anew. The downward pressure is significant, with five days of selling before the day of recovery.
In the past few days, the fate of TTNP was shared by several pharmaceutical tickers, which traditionally quickly lose their glitter. La Jolla Pharmaceutical, Co. (OTCBB:LJPC) is falling for a second day in a row, wiping out around a fifth of its value, moving away from the 24-cent peak.
Biozone Pharmaceuticals, Inc. (OTCBB:BZNE) is another concern of the last day where a takeoff was expected, and instead a tangled mess of erratic movements happened, with selling still prevailing. BZNE stands at 68 cents, with a negligible fall compared to the previous day, as nearly 10 million shares were shed in decreasing volumes in the past four days.
If you are still waiting for clarity with TTNP, it may never arrive. It is best not to rely too much on another one of those great positive developments, and instead to decide on an affordable investment and a desirable outcome. While TTNP has a solid background compared to other pharmaceutical companies, the latest Probruphine therapy is threatening to take enough troubles to the surface.
The pharmaceutical sector is remaining extremely active right now, with newcomers and old names returning. Yet in the past few days, a lot of positive trends broke suddenly. If you cannot afford losses of a significant part of your investment, avoid investing in those peaking tickers, since the correction comes without warning.
